Cough Triggers and Symptoms Among Patients with Refractory or Unexplained Chronic Cough in Two Phase 3 Trials of the P2X3 Receptor Antagonist Gefapixant (COUGH-1 and COUGH-2)

被引：0
|
作者：
Morice, Alyn [1 ]
Birring, Surinder [2 ]
Dicpinigaitis, Peter [3 ]
McGarvey, Lorcan
Pavord, Ian [4 ]
Smith, Jaclyn [5 ]
La Rosa, Carmen [6 ]
Li, Qing [6 ]
Nguyen, Allison Martin [6 ]
Schelfhout, Jonathan [6 ]
Tzontcheva, Anjela [6 ]
Muccino, David [6 ]
机构：
[1] Univ Hull, Kingston Upon Hull, N Humberside, England
[2] Kings Coll London, London, England
[3] Jack D Weiler Hosp, Bronx, NY USA
[4] Univ Oxford, Oxford, England
[5] Univ Manchester, Manchester, Lancs, England
[6] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2021年 / 147卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
188
引用
收藏
页码：AB61 / AB61
页数：1
相关论文
共 50 条
  • [1] Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough
    Muccino, David R.
    Morice, Alyn H.
    Birring, Surinder S.
    Dicpinigaitis, Peter, V
    Pavord, Ian D.
    Assaid, Christopher
    Kleijn, Huub Jan
    Hussain, Azher
    La Rosa, Carmen
    McGarvey, Lorcan
    Smith, Jaclyn A.
    ERJ OPEN RESEARCH, 2020, 6 (04) : 1 - 11
  • [2] Rationale and Design of Two, Phase 3, Randomized Controlled Trials (COUGH-1 and COUGH-2) of Gefapixant, A P2x3 Receptor Antagonist, in Refractory and Unexplained Chronic Cough
    Muccino, D.
    Morice, A. H.
    Birring, S. S.
    McGarvey, L.
    Dicpinigaitis, P.
    Pavord, I. D.
    Tershakovec, A. M.
    Kitt, M. M.
    Zheng, Y.
    Assaid, C.
    Smith, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [3] Late Breaking Abstract - Two Phase 3 Randomized Clinical Trials of Gefapixant, a P2X3 Receptor Antagonist, in Refractory or Unexplained Chronic Cough (COUGH-1 and COUGH-2)
    McGarvey, Lorcan
    Birring, Surinder
    Morice, Alyn
    Dicpinigaitis, Peter
    Pavord, Ian
    Schelfhout, Jonathan
    Nguyen, Allison Martin
    Li, Qing
    Tzontcheva, Anjela
    Iskold, Beata
    Green, Stuart
    La Rosa, Carmen
    Muccino, David
    Smith, Jaclyn
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [4] Dose Selection for Two, Phase 3, Randomized Controlled Trials (Cough-1 and Cough-2) in Refractory or Unexplained Chronic Cough
    Hussain, A.
    La Rosa, C.
    Tershakovec, A.
    Kleijn, H. Jan
    Muccino, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [5] Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
    McGarvey, Lorcan P.
    Birring, Surinder S.
    Morice, Alyn H.
    Dicpinigaitis, Peter V.
    Pavord, Ian D.
    Schelfhout, Jonathan
    Nguyen, Allison Martin
    Li, Qing
    Tzontcheva, Anjela
    Iskold, Beata
    Green, Stuart A.
    La Rosa, Carmen
    Muccino, David R.
    Smith, Jaclyn A.
    LANCET, 2022, 399 (10328): : 909 - 923
  • [6] Comorbid Conditions and Medical History Among Patients with Refractory or Unexplained Chronic Cough in Two Phase 3 Clinical Trials (COUGH-1 and COUGH-2)
    Dicpinigaitis, Peter
    Birring, Surinder
    McGarvey, Lorcan
    Morice, Alyn
    Pavord, Ian
    Smith, Jaclyn
    La Rosa, Carmen
    Li, Qing
    Nguyen, Allison Martin
    Schelfhout, Jonathan
    Tzontcheva, Anjela
    Muccino, David
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB61 - AB61
  • [7] Baseline characteristics from a phase 3, randomized controlled trial (COUGH-1) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough
    Muccino, D.
    Morice, A.
    Birring, S. S.
    Mcgarvey, L.
    Dicpinigaitis, P., V
    Pavord, I. D.
    La Rosa, C.
    Urdaneta, E.
    Assaid, C.
    Smith, J. A.
    ALLERGY, 2020, 75 : 339 - 340
  • [8] BASELINE CHARACTERISTICS FROM A PHASE 3, RANDOMIZED CONTROLLED TRIAL (COUGH-2) OF GEFAPIXANT, A P2X3 RECEPTOR ANTAGONIST, IN REFRACTORY OR UNEXPLAINED CHRONIC COUGH
    Muccino, D.
    Morice, A.
    Birring, A.
    Mcgarvey, L.
    Dicpinigaitis, P.
    Pavord, I.
    La Rosa, C.
    Urdaneta, E.
    Assaid, C.
    Smith, J.
    CHEST, 2020, 157 (06) : 4A - 4A
  • [9] Objective Cough Frequency with Gefapixant in Chronic Cough: A Pooled Analysis of Two Phase 3 Randomized, Controlled Clinical Trials (COUGH-1 and COUGH-2)
    Smith, J.
    Morice, A. H.
    Mcgarvey, L.
    Pavord, I. D.
    Birring, S. S.
    Dicpinigaitis, P.
    Iskold, B.
    Li, Q.
    Tzontcheva, A.
    La Rosa, C.
    Muccino, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [10] POOLED ANALYSIS OF OBJECTIVE COUGH FREQUENCY IN PARTICIPANTS WITH CHRONIC COUGH TREATED WITH GEFAPIXANT IN TWO PHASE 3 CLINICAL TRIALS (COUGH-1 AND COUGH-2)
    Smith, J. A.
    Morice, A.
    McGarvey, L.
    Pavord, I.
    Birring, S. S.
    Dicpinigaitis, P.
    Iskold, B.
    Li, Q.
    Tzontcheva, A.
    La Rosa, C.
    Muccino, D.
    THORAX, 2021, 76 : A99 - A100
12345